Tissue Diagnostics Market Size to Surpass USD 9.04 Bn By 2032

The global tissue diagnostics market size was valued at USD 4.75 billion in 2022 and is projected to surpass around USD 9.04 billion by 2032, expanding at a remarkable CAGR of 6.7% from 2023 to 2032.

The global tissue diagnostics market size accounted for USD 5.04 billion in 2023. North America has held the maximum market share in 2022.

Tissue diagnostics examines tissue samples extracted from the human body to diagnose diseases, assess their severity, and guide treatment decisions. This process involves a detailed analysis of tissue structures to identify abnormalities, enabling healthcare professionals to make informed decisions about patient care. It plays a critical role in understanding the nature and extent of diseases, contributing to accurate diagnoses and personalized treatment strategies.

Download the Sample Copy@ https://www.precedenceresearch.com/sample/2475

Tissue diagnosis is crucial for cancer detection, serving as a gold standard procedure. Technological advancements, including the widespread adoption of automated tissue-based diagnostic systems, enable researchers to conduct timely diagnoses and detect early-stage cancer and other diseases.

The Control Research Network and Cancer Prevention event, organized by domestic centers in North America, focuses on preventing and controlling various diseases, particularly cancer prevention. For instance, modified drugs rely on human tissue to grow advanced tests. Integrating advanced technologies and healthcare I.T. systems into clinical routines has significantly enhanced personalized medicine by driving the utilization of the tissue diagnostics market. The Medicine Enterprise in the United States contributes to the advancement of the personalized pharmaceutical industry.

Growth Factors:

• The growth of the tissue diagnostics market is attributed to the increasing global prevalence of cancer, the presence and exploration of biomarkers, guidelines advocating cancer screening, a surge in clinical trials for oncology drugs, and the accessibility of tissue-based companion diagnostics. Additionally, the expanding emphasis on personalized healthcare and advancements in digital pathology and tissue diagnosis automation presents substantial opportunities for market growth.
• Tissue-based diagnostics are a pivotal technique in cancer diagnosis, extensively applied in oncology. The increasing prevalence of cancer contributes to a rising demand for tissue diagnostics. For instance, the October 2022 report from Macmillan Cancer Support highlighted a rising cancer incidence in the United Kingdom (U.K.). The projected increase in the number of people living with cancer in the U.K. is expected to reach 4 million by 2030, up from 3.5 million in 2025.
• The increasing geriatric population, coupled with a growing prevalence of cancer, has led to a significant demand and rapid expansion in the tissue diagnostics market. Ageing increases the likelihood of chronic diseases among the geriatric population, including cancer and tumors. The incidence of these diseases is notably higher in males than in females. Cancer, being a complex disease, evolves through various stages of carcinogenesis involving diverse processes.
• Companies in the field are investing significantly in research and development to enhance tissue diagnostics technology, aiming to improve accuracy and introduce innovative products

Regional Stance:

In 2022, North America held the most revenue share and dominated the global tissue diagnostics market. One of the main factors propelling the tissue diagnostics market in this region is the rising incidence of cancer among people, which is related to the growing elderly population. Numerous community events both lower the number of cancer patients and raise demand for improved cancer detection technologies in the tissue diagnostics industry.

Furthermore, the Control Research Network and Cancer Prevention is a national initiative involving domestic centres aimed at controlling and preventing cancer in North America. But the development of more sophisticated testing for Modified Drug essentially depends on the utilisation of human tissue. The application of tissue diagnostics is driven by the growth in sophisticated technologies and healthcare IT systems in clinical routines, which has greatly improved modified medicine. The US-based Medicine Enterprise advances the customised pharmaceutical market.

For the duration of the projection period, the Asia Pacific region is anticipated to maintain a notable CAGR. This region’s growth has been aided by greater access to a range of tissue diagnostic tests provided by global enterprises, which in turn has expanded the tissue diagnostic market in this area. For example, a deal for the marketing of the Immunoscore diagnostic studies in China was signed on April 19, 2019, between Genecast and HalioDx SAS. The availability of this product for Chinese cancer patients has expanded as a result of this programme.

Ask Here for Customization@ https://www.precedenceresearch.com/customization/2475

Tissue Diagnostics Market Scope

Market Potential:

The breast cancer segment maintains a significant market share and is poised to continue this trajectory throughout the forecast period due to the escalating global burden of breast cancer. For instance, the American Cancer Society’s 2023 report estimates that approximately 13% of women in the United States will develop invasive breast cancer in their lifetime. The report underscores breast cancer as one of the most prevalent forms of cancer diagnosed in the U.S., projecting around 300.6 thousand new cases in 2023 compared to 290.6 thousand patients in 2022.

The segment’s growth is anticipated to be bolstered by new product launches from key market players. The increasing demand for technologically advanced tissue diagnostics products, driven by the need for accurate cancer diagnostics and disease monitoring, contributes to this trend. As an illustration, in September 2023, Ibex Medical Analytics introduced Galen Breast HER2, an artificial intelligence-powered solution. This innovative tool assists pathologists in achieving a higher standard for accurate and reproducible HER2 (human epidermal growth factor receptor 2) scoring in patients with breast cancer.

The tissue diagnostics market is shifting towards automation, driven by improved assay performance, cost reduction, and efficiency. Challenges like managing large datasets and a shortage of skilled pathologists are boosting the demand for automated solutions, including advanced staining equipment and digital immunohistochemistry platforms. Moreover, the emergence of advanced laboratory information systems (LIS) and integrated workflow solutions is shaping the market’s future. Collaborations with anatomic pathology LIS (APLIS) vendors and partnerships with instrument distributors in emerging markets are crucial in advancing the field.

Related Reports:

• Tissue Engineering Market: The global tissue engineering market size is projected to grow to USD 33.38 billion by 2032 from USD 11.81 billion in 2022, representing a CAGR of 11% over the forecast period 2023 to 2032.
• Cell and Tissue Preservation Market: The global cell and tissue preservation market size was accounted at USD 3.80 billion in 2022 and it is expected to hit around USD 10.74 billion by 2032, expanding at a CAGR of 11% during the forecast period 2023 to 2032.
• Cell Expansion Market: The global cell expansion market size was valued at USD 15.72 billion in 2022 and it is expected to hit over USD 50.82 billion by 2032 with a remarkable CAGR of 12.5% from 2023 to 2032.

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 650 460 3308

Industry Spotlight:

• In July 2023, Quest Diagnostics introduced a pioneering tissue-based prostate cancer biomarker test, AmeriPath, through its specialised pathology division. Collaborating with Australia-based Envision Sciences, the test aims to meet the critical clinical demand for identifying and distinguishing potentially aggressive cases of prostate cancer in men.
• In March 2023, Aptamer Group innovated a new reagent, Optimer-Fc, designed for automated immunohistochemistry (IHC) workflows. This reagent facilitates the detection of cancer cells or other disease markers.
• In March 2023, Lunaphore, a Swiss medtech company at the forefront of spatial biology techniques for tissue diagnostics, revealed the successful closure of a Series D funding round. Notably recognised as a Venture Kick winner, a TOP 100 Startup and Scale-Up, and a Venture Leader alum, Lunaphore continues to make strides in advancing innovative solutions in tissue diagnostics.
• In May 2022, Leica Biosystems, a German-based company, introduced the BOND-PRIME, an innovative staining solution designed to enhance laboratory diagnostic efficiency. This system empowers lab technicians by allowing them to load slides in any combination, with any reagent, at any time, providing a flexible and streamlined approach to diagnostic processes.

Recent Developments:

QIAGEN N.V. (QGEN) has unveiled three new kits for deployment on its QIAcuity systems, accompanied by a substantial software update. These innovations aim to broaden the scope of applications for digital PCR (Polymerase Chain Reaction) technology, encompassing cell and gene therapies, DNA and RNA quantification, and safety assessments in food and pharmaceuticals.

Company Synopsis:

Siemens

Siemens Limited is a technology company with a strategic focus on industry, infrastructure, digital transformation, and the transportation, transmission, and generation of electrical power.

Recent business activity

In June 2023, Siemens (SIEGn.DE) revealed a 2 billion euros ($2.2 billion) global investment plan to bolster its operations against disruptions and geopolitical challenges. The initiative includes the construction of new factories, research centres, and training sites worldwide, aligning with Siemens’ strategy to capitalise on stimulus packages in the United States and Europe.

QIAGEN

QIAGEN specialises in delivering sample and assay technologies for molecular diagnostics, applied testing, as well as academic and pharmaceutical research

Market Key Players:

• Abbott Laboratories
• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific Inc.
• Danaher
• Siemens
• bioMérieux SA
• QIAGEN
• GE Healthcare
• Becton, Dickinson and Company
• Merck KGaA

Market Segmentation

By Application

• Prostate Cancer
• Breast Cancer
• Lung Cancer
• Gastric Cancer
• Other Cancers

By Product

• In Situ Hybridization
  • consumables
  • Instruments
  • Software
• Immunohistochemistry
  • Instruments
    
    • Slide Staining Systems
    • Tissue Microarrays
    • Tissue Processing Systems
    • Slide Scanners
    • Other Products
  • Consumables
  • Antibodies
  • Reagents
  • Kits
• Digital Pathology and workflow
  • Whole Slide Imaging
  • Image Analysis Informatics
  • Information Management System Storage & Communication
• Primary and Special Staining
• Anatomic Pathology
  • Instruments
  • Microtomes & Cryostat Microtomes
  • Tissue Processors
  • Automatic Strainers
  • Other Products
  • Consumables
  • Reagents & Antibodies
  • Probes & Kits
  • Others

By End-User

• Research Laboratories
• Hospitals
• Contract Research Organizations (CROs)
• Pharmaceutical Organizations

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)

Browse Table of Contents: https://www.precedenceresearch.com/table-of-content/2475

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Immediate Delivery Available | Buy This Premium Research Report@ https://www.precedenceresearch.com/checkout/2475

Unlocking Market Insights through Data Excellence

The “Precedence Statistics” flexible dashboard is a powerful tool that offers real-time news updates, economic and market forecasts, and customizable reports. It can be configured to support a wide range of analysis styles and strategic planning needs. This tool empowers users to stay informed and make data-driven decisions in various scenarios, making it a valuable asset for businesses and professionals looking to stay ahead in today’s dynamic and data-driven world.

Access our Premium Real Time Data Intelligence Tool, Visit: www.precedencestatistics.com

About Us

Precedence Research is a worldwide market research and consulting organization. We give an unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.

Web: https://www.precedenceresearch.com/

Our Blogs:

https://www.towardshealthcare.com

https://www.towardspackaging.com

For Latest Update Follow Us:

Linkedin | Facebook | Twitter